Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, Canada.
Department of Small Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
J Vet Med Sci. 2024 Sep 10;86(9):979-985. doi: 10.1292/jvms.24-0100. Epub 2024 Jul 19.
No study has determined the minimal effective dose of trazodone required to induce behavioral changes and its safety profile in rabbits. Therefore, this study aimed to determine the minimal effective dose of trazodone to improve compliance to handling, and to evaluate associated changes in motor activity, physiological and arterial blood gas parameters. Eight intact female New Zealand White rabbits (2-month-old; 1.66 ± 0.12 kg) were included in this prospective, blinded, randomized cross-over study. After a 10-day acclimation, rabbits randomly received placebo or trazodone 10, 20 or 30 mg/kg orally (PLAC, TRAZ10, TRAZ20, TRAZ30) with a 1-week wash-out period. Compliance scoring (dynamic interactive visual analog scale; DIVAS), activity levels measured with accelerometry (T0-T600), physiological parameters (temperature, heart, and respiratory rates), and arterial blood gas parameters (up to T240) were evaluated. Compliance scores, accelerometry, physiological and arterial blood gas parameters and hypoxemia prevalence (PaO <60 mmHg) were analyzed using linear mixed models and Chi-squared tests, respectively (P<0.05). When compared with PLAC, DIVAS scores were significantly higher at T80-120, T40-120 and T120-200 in TRAZ10, TRAZ20 and TRAZ30 post-administration, respectively. When compared with baseline, DIVAS scores were significantly higher from T80-160, T40-240 and T80-200 in TRAZ10, TRAZ20 and TRAZ30, respectively. All other parameters were not significantly different. In TRAZ30, hypoxemia was observed in 2/8 rabbits (P=0.104). In conclusion, oral trazodone improved rabbit compliance at all studied dosages, especially 20 mg/kg improved rabbit compliance without decreasing motor activity or causing hypoxemia.
尚无研究确定曲唑酮诱导行为改变的最小有效剂量及其在兔中的安全性。因此,本研究旨在确定曲唑酮的最小有效剂量以提高对处理的依从性,并评估相关运动活动、生理和动脉血气参数的变化。
本前瞻性、盲法、随机交叉研究纳入了 8 只 2 月龄(1.66 ± 0.12 kg)的新西兰白兔。经过 10 天的适应期,兔子随机接受安慰剂或曲唑酮 10、20 或 30 mg/kg 口服(PLAC、TRAZ10、TRAZ20、TRAZ30),间隔 1 周洗脱期。采用动态互动视觉模拟量表(DIVAS)进行依从性评分,通过加速度计测量活动水平(T0-T600),评估生理参数(体温、心率和呼吸频率)和动脉血气参数(最多至 T240)。采用线性混合模型和卡方检验分别分析依从性评分、加速度计、生理和动脉血气参数以及低氧血症的发生率(PaO <60 mmHg)(P<0.05)。
与 PLAC 相比,在 TRAZ10、TRAZ20 和 TRAZ30 给药后 T80-120、T40-120 和 T120-200 时,DIVAS 评分显著升高;与基线相比,在 TRAZ10、TRAZ20 和 TRAZ30 时,DIVAS 评分在 T80-160、T40-240 和 T80-200 时显著升高。其他所有参数均无显著差异。在 TRAZ30 中,有 2/8 只兔子出现低氧血症(P=0.104)。
综上所述,口服曲唑酮可提高所有研究剂量兔的依从性,尤其 20 mg/kg 可改善兔的依从性,而不降低运动活动或导致低氧血症。